Free Trial

Keros Therapeutics (KROS) Competitors

Keros Therapeutics logo
$14.16 +0.12 (+0.85%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$14.00 -0.16 (-1.13%)
As of 04:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KROS vs. AMRX, AAPG, MIRM, OGN, APLS, ARWR, GMTX, VCEL, BLTE, and NAMS

Should you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Amneal Pharmaceuticals (AMRX), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Organon & Co. (OGN), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Gemini Therapeutics (GMTX), Vericel (VCEL), Belite Bio (BLTE), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

Keros Therapeutics vs.

Amneal Pharmaceuticals (NASDAQ:AMRX) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk, media sentiment and community ranking.

Amneal Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$2.83B0.80-$83.99M-$0.04-179.75
Keros Therapeutics$214.71M2.68-$152.99M-$0.18-78.67

Keros Therapeutics received 47 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 70.53% of users gave Keros Therapeutics an outperform vote.

CompanyUnderperformOutperform
Amneal PharmaceuticalsOutperform Votes
20
95.24%
Underperform Votes
1
4.76%
Keros TherapeuticsOutperform Votes
67
70.53%
Underperform Votes
28
29.47%

Amneal Pharmaceuticals currently has a consensus price target of $11.50, indicating a potential upside of 59.94%. Keros Therapeutics has a consensus price target of $37.00, indicating a potential upside of 161.30%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amneal Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Keros Therapeutics
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.57

Amneal Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of -6.88% compared to Keros Therapeutics' net margin of -27,890.94%. Keros Therapeutics' return on equity of -41.74% beat Amneal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amneal Pharmaceuticals-6.88% -346.26% 4.85%
Keros Therapeutics -27,890.94%-41.74%-38.42%

In the previous week, Keros Therapeutics had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 9 mentions for Keros Therapeutics and 7 mentions for Amneal Pharmaceuticals. Keros Therapeutics' average media sentiment score of 1.34 beat Amneal Pharmaceuticals' score of 1.01 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amneal Pharmaceuticals
6 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Keros Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Keros Therapeutics beats Amneal Pharmaceuticals on 10 of the 18 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KROS vs. The Competition

MetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$575.11M$6.48B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-2.729.0626.7119.71
Price / Sales2.68251.50386.13120.55
Price / CashN/A65.8538.2534.62
Price / Book1.286.456.774.50
Net Income-$152.99M$143.98M$3.23B$248.22M
7 Day Performance0.93%2.41%1.80%0.56%
1 Month Performance1.94%4.56%11.10%13.17%
1 Year Performance-72.30%-2.67%17.11%7.30%

Keros Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KROS
Keros Therapeutics
3.2455 of 5 stars
$14.16
+0.9%
$37.00
+161.3%
-72.3%$575.11M$214.71M-2.72100Positive News
AMRX
Amneal Pharmaceuticals
3.2546 of 5 stars
$7.19
-1.2%
$11.50
+60.1%
+8.1%$2.26B$2.83B-10.587,600Positive News
AAPG
Ascentage Pharma Group International
N/A$25.50
+1.5%
N/AN/A$2.22B$980.65M0.00600News Coverage
Positive News
Gap Down
MIRM
Mirum Pharmaceuticals
4.0709 of 5 stars
$44.01
-0.7%
$60.73
+38.0%
+68.0%$2.19B$379.25M-21.85140Positive News
Analyst Revision
OGN
Organon & Co.
4.7951 of 5 stars
$8.40
-0.4%
$18.00
+114.4%
-60.4%$2.18B$6.29B2.5210,000
APLS
Apellis Pharmaceuticals
4.2027 of 5 stars
$17.30
-0.7%
$40.42
+133.7%
-59.2%$2.18B$775.84M-8.53770Analyst Forecast
ARWR
Arrowhead Pharmaceuticals
3.5164 of 5 stars
$15.34
+0.2%
$42.13
+174.7%
-38.8%$2.12B$545.21M-2.97400News Coverage
Analyst Forecast
Analyst Revision
GMTX
Gemini Therapeutics
N/A$48.89
-2.4%
N/A+56.4%$2.12BN/A-48.8930News Coverage
VCEL
Vericel
2.6721 of 5 stars
$41.09
+0.0%
$61.14
+48.8%
-17.8%$2.07B$238.54M686.61300Positive News
Analyst Forecast
BLTE
Belite Bio
2.0346 of 5 stars
$63.84
-5.1%
$96.67
+51.4%
+43.5%$2.03BN/A-57.5110Analyst Downgrade
NAMS
NewAmsterdam Pharma
2.6699 of 5 stars
$18.41
-0.5%
$43.00
+133.6%
-6.6%$2.03B$47.14M-9.844Positive News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:KROS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners